GCG and sarcopenia: In addition, bone-specific assessments were not systematically collected in the subgroup treated with GLP-1 RAs; therefore, we could not evaluate bone health or musculoskeletal safety, which is particularly relevant in the context of emerging concerns that long-term GLP-1 RA therapy may be associated with sarcopenia and potential bone loss.